ClinicalTrials.gg
RecruitingNCT07602582Updated Oct 28, 2026

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

A Phase 3 interventional study of Donanemab and Placebo in Alzheimer Disease, Dementia and Plaque, Amyloid, sponsored by Eli Lilly and Company. Recruiting at 62 sites in 3 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 28, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.

Planned enrollment
4th of 15
550 · median 240
Started
2026
with 6 others
Phase 3
6 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
12 of 15
Eli Lilly and Company

Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 4th largest by planned enrollment, is one of 7 that started in 2026, is one of 6 in phase 3, and was the 14th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About donanemab

donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing donanemab in Alzheimer Disease, or all of them as a file.
02

Study summary

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

03

Conditions studied

  • Alzheimer Disease
  • Dementia
  • Plaque, Amyloid

Keywords

  • Donanemab
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed study AACM Addendum 7.
  • Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
  • Are individuals assigned female at birth who are not of , or are individuals assigned male at birth.
  • use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Current serious or unstable illnesses that, in the investigator's opinion, could interfere with participation in this study.
  • Have any for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.
  • Have any intracranial abnormality or lesion, including but not limited to macrohemorrhage, inflammation, or structural findings that, in the opinion of the investigator, may pose an unacceptable safety risk to the participant. Screening MRI finding of amyloid-related imaging abnormalities with edema (ARIA-E) may be monitored for resolution.
  • Contraindication to florbetapir F 18 PET.
  • Have had history of amyloid-targeting therapy treatment outside donanemab trials.
  • Have participated, within the last 30 days, in a clinical trial involving a study intervention judged not to be scientifically or medically compatible with this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Donanemab

    Donanemab administered intravenously (IV)

    Drug: Donanemab

  • Placebo comparator
    Placebo

    Placebo IV

    Drug: Placebo

Interventions

  • Administered IV

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB)

    Time frame: Baseline through Week 130

Secondary outcomes

  1. Change from Baseline as Measured by Cognitive Function Index (CFI)

    Time frame: Baseline through Week 130

  2. Change from Baseline in Brain Amyloid Plaque Levels as Measured by Florbetapir F 18 Positron Emission Tomography (PET) Scan.

    Time frame: Baseline through Week 130

  3. Change From Baseline in Plasma Phosphorylated Tau at Threonine 217 (P-tau217)

    Time frame: Baseline through Week 130

  4. Pharmacokinetics (PK): Peak Concentrations of Serum Donanemab

    Time frame: Baseline, Week 52, Week 104

07

Study locations

60 of 62 sites recruiting
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
    Recruiting
    • · Contact602-839-6900
    • Po-Heng Tsai · Principal investigator
  • Care Access - Huntington Beach
    Huntington Beach, California 92648, United States
    Recruiting
    • · Contact714-378-2440
    • Christine Thai · Principal investigator
  • Irvine Clinical Research
    Irvine, California 92614, United States
    Recruiting
    • · Contact949-753-1663
    • Elly Lee · Principal investigator
  • Healthy Brain Clinic
    Long Beach, California 90804, United States
    Recruiting
    • · Contact562-606-5999
    • Dung Trinh · Principal investigator
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
    Recruiting
    • · Contact951-374-1190
    • Jack Vu · Principal investigator
  • Headlands Research- Sacramento
    Sacramento, California 95821, United States
    Recruiting
    • · Contact916-434-8230
    • Jeffrey Wayne · Principal investigator
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
    Recruiting
    • · Contact858-278-3647
    • Eric Chavez · Principal investigator
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
    Recruiting
    • · Contact714-542-3008
    • John Duffy · Principal investigator
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
    Recruiting
    • · Contact707-521-3830
    • Allan Bernstein · Principal investigator
  • Infectious Disease Doctors Medical Group, APC
    Walnut Creek, California 94598, United States
    Recruiting
    • · Contact925-947-2334
    • Bhavna Malik · Principal investigator
  • VIN - Aventura
    Aventura, Florida 33180, United States
    Recruiting
    • · Contact305-933-5993
    • Jonathan Cross · Principal investigator
  • Bradenton Research Center, Inc.
    Bradenton, Florida 34205, United States
    Recruiting
    • · Contact941-708-0005
    • Eric Folkens · Principal investigator
  • K2 Medical Research WINTER GARDEN
    Clermont, Florida 34711, United States
    Recruiting
    • · Contact321-234-0199
    • Christopher Galloway · Principal investigator
  • K2 Medical Research - Daytona Beach
    Daytona Beach, Florida 32114, United States
    Recruiting
    • Joshua Eisenhut · Principal investigator
  • Finlay Medical Research
    Greenacres City, Florida 33467, United States
    Recruiting
    • · Contact561-766-2181
    • Jorge Calle Medina · Principal investigator
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
    Recruiting
    • · Contact904-730-0101
    • Steven Toenjes · Principal investigator
  • K2 MEDICAL Research THE VILLAGES
    Lady Lake, Florida 32159, United States
    Recruiting
    • · Contact352-500-5252
    • Craig Curtis · Principal investigator
  • K2 Medical Research ORLANDO
    Maitland, Florida 32751, United States
    Recruiting
    • · Contact407-500-5252
    • Brandon Lenox · Principal investigator
  • Merritt Island Medical Research, LLC
    Merritt Island, Florida 32952, United States
    Recruiting
    • David Kirk · Principal investigator
  • Finlay Medical Research
    Miami, Florida 33126, United States
    Recruiting
    • Lilia Rodriguez Ables · Principal investigator
  • VIN-Andrew Lerman
    Miami, Florida 33133, United States
    Recruiting
    • · Contact786-655-8010
    • Andrew Lerman · Principal investigator
  • Indago Research & Health Center, Inc
    Miami Lakes, Florida 33016, United States
    Recruiting
    • · Contact305-825-6588
    • Jose Cardona · Principal investigator
  • Adult Medicine of Lake County, Inc.
    Mt. Dora, Florida 32757, United States
    Recruiting
    • · Contact352-383-8222
    • Shirley Nagel · Principal investigator
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
    Recruiting
    • · Contact727-849-4131
    • Cathy Barnes · Principal investigator
  • Charter Research - Orlando
    Orlando, Florida 32803, United States
    Recruiting
    • · Contact407-337-3000
    • Edgardo Rivera-Rivera · Principal investigator
  • Headlands Research Orlando
    Orlando, Florida 32806, United States
    Recruiting
    • · Contact407-705-3471
    • Uzma Khan · Principal investigator
  • Emerald Coast Neurology - Airport Boulevard
    Pensacola, Florida 32504, United States
    Recruiting
    • · Contact850-438-1136
    • David Bear · Principal investigator
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
    Recruiting
    • · Contact386-304-7070
    • Alexander White · Principal investigator
  • Care Access - Tampa
    Tampa, Florida 33625, United States
    Recruiting
    • · Contact877-791-0656
    • Brad Lipson · Principal investigator
  • K2 Medical Research - Tampa
    Tampa, Florida 33634, United States
    Recruiting
    • · Contact813-800-5252
    • Kelley Wilson · Principal investigator
  • Charter Research - The Villages
    The Villages, Florida 32162, United States
    Recruiting
    • · Contact352-441-2000
    • Jeffrey Norton · Principal investigator
  • Conquest Research
    Winter Park, Florida 32789, United States
    Recruiting
    • · Contact407-916-0060
    • Rekha Gandhi · Principal investigator
  • Center for Advanced Research & Education
    Gainesville, Georgia 30501, United States
    Recruiting
    • · Contact770-534-5154
    • Angela Ritter · Principal investigator
  • North Georgia Clinical Research
    Woodstock, Georgia 30189, United States
    Recruiting
    • · Contact678-494-5735
    • Bram Wieskopf · Principal investigator
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
    Recruiting
    • · Contact208-685-0600
    • Brock McConnehey · Principal investigator
  • Great Lakes Clinical Trials - Andersonville
    Chicago, Illinois 60640, United States
    Recruiting
    • · Contact773-275-3500
    • Jeffrey Ross · Principal investigator
  • Care Access - South Indianapolis
    Indianapolis, Indiana 46254, United States
    Recruiting
    • · Contact877-791-0656
    • Gigi Lefebvre · Principal investigator
  • Josephson Wallack Munshower Neurology, PC
    Indianapolis, Indiana 46256, United States
    Recruiting
    • · Contact317-537-6099
    • Kristi George · Principal investigator
  • Covenant Medical Center
    Waterloo, Iowa 50702, United States
    Recruiting
    • · Contact319-272-2112
    • NICHOLAS GOETSCH · Principal investigator
  • Care Access - Lake Charles (Bayou Pines)
    Lake Charles, Louisiana 70601, United States
    Recruiting
    • · Contact337-602-6642
    • Jason Morris · Principal investigator
  • Boston Center for Memory
    Newton, Massachusetts 02459, United States
    Recruiting
    • · Contact617-699-6927
    • Paul Solomon · Principal investigator
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
    Recruiting
    • · Contact617-744-1310
    • David DiBenedetto · Principal investigator
  • Revival Research Institute, LLC
    Southfield, Michigan 48075, United States
    Recruiting
    • · Contact586-276-7453
    • Abdulhassan Saad · Principal investigator
  • Citizens Memorial Hospital District
    Bolivar, Missouri 65613, United States
    Recruiting
    • · Contact417-328-7781
    • Curtis Schreiber · Principal investigator
  • Vector Clinical Trials
    Las Vegas, Nevada 89128, United States
    Recruiting
    • · Contact702-750-000
    • Bharat Mocherla · Principal investigator
  • The Cognitive and Research Center of New Jersey
    Springfield, New Jersey 07081, United States
    Recruiting
    • Raminder Parihar · Principal investigator
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
    Recruiting
    • · Contact704-283-7359
    • Awawu Igbinadolor · Principal investigator
  • NDx Clinical Research, Inc.
    Dayton, Ohio 45459, United States
    Recruiting
    • · Contact937-224-8200
    • Joel Vandersluis · Principal investigator
  • Care Access - Lima
    Lima, Ohio 45805, United States
    Recruiting
    • · Contact877-791-0656
    • Gigi Lefebvre · Principal investigator
  • Senior Adults Specialty Research
    Austin, Texas 78757, United States
    Recruiting
    • · Contact512-407-8628
    • John Bertelson · Principal investigator
  • Gadolin Research
    Beaumont, Texas 77702, United States
    Recruiting
    • · Contact409-331-6040
    • Joseph Oommen · Principal investigator
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77054, United States
    Recruiting
    • · Contact713-486-0536
    • David Hunter · Principal investigator
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
    Recruiting
    • · Contact210-545-4900
    • Michelle Welch · Principal investigator
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
    Recruiting
    • Jeena Vaid · Principal investigator
  • Universal Research Group
    Tacoma, Washington 98405, United States
    Recruiting
    • · Contact253-882-1070
    • Sabrina Benjamin · Principal investigator
  • Tokyo-Eki Center-building Clinic
    Chūōku, 103-0027, Japan
    Recruiting
    • · Contact81120023812
    • Arihiro Kiyosue · Principal investigator
  • P-One Clinic
    Hachiōji, 192-0071, Japan
    Recruiting
    • · Contact81120023812
    • Kenichi Furihata · Principal investigator
  • National Center for Geriatrics and Gerontology
    Ōbu, 474-8511, Japan
    Not yet recruiting
    • · Contact81120023812
    • MASASHI TSUJIMOTO · Principal investigator
  • Samoncho Clinic
    Shinjuku, 160-0017, Japan
    Not yet recruiting
    • · Contact81120023812
    • Takahiro Yokoyama · Principal investigator
  • Yotsuya Internal Medicine Clinic
    Shinjyuku, 160-0017, Japan
    Recruiting
    • · Contact81120023812
    • takahiro yokoyama · Principal investigator
  • Tokyo Metropolitan Institute for Geriatrics and Gerontology
    tabashi City, 173-0015, Japan
    Recruiting
    • · Contact81120023812
    • Atsushi Iwata · Principal investigator
  • SCB Research Center
    Bayamón, 00961, Puerto Rico
    Recruiting
    • · Contact(787) 798-4592
    • William Julio · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2029, 40 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 40 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
May 22, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed. 15 sites changed recruiting status (15 now recruiting)
Show 15 sites
  • Banner Alzheimer's Institute · Phoenix, United StatesNot yet recruiting→Recruiting
  • Artemis Institute for Clinical Research · San Diego, United StatesNot yet recruiting→Recruiting
  • K2 Medical Research - Tampa · Tampa, United StatesNot yet recruiting→Recruiting
  • Covenant Medical Center · Waterloo, United StatesNot yet recruiting→Recruiting
  • MedVadis Research Corporation · Waltham, United StatesNot yet recruiting→Recruiting
  • Revival Research Institute, LLC · Southfield, United StatesNot yet recruiting→Recruiting
  • Monroe Biomedical Research · Monroe, United StatesNot yet recruiting→Recruiting
  • NDx Clinical Research, Inc. · Dayton, United StatesNot yet recruiting→Recruiting
  • Senior Adults Specialty Research · Austin, United StatesNot yet recruiting→Recruiting
  • Consano Clinical Research, LLC · Shavano Park, United StatesNot yet recruiting→Recruiting
  • Tokyo-Eki Center-building Clinic · Chūōku, JapanNot yet recruiting→Recruiting
  • P-One Clinic · Hachiōji, JapanNot yet recruiting→Recruiting
  • Yotsuya Internal Medicine Clinic · Shinjyuku, JapanNot yet recruiting→Recruiting
  • Tokyo Metropolitan Institute for Geriatrics and Gerontology · tabashi City, JapanNot yet recruiting→Recruiting
  • SCB Research Center · Bayamón, Puerto RicoNot yet recruiting→Recruiting
Show 4 added (4 United States)
  • Headlands Research- Sacramento · Sacramento, United States
  • K2 Medical Research WINTER GARDEN · Clermont, United States
  • K2 Medical Research - Daytona Beach · Daytona Beach, United States
  • K2 MEDICAL Research THE VILLAGES · Lady Lake, United States
Show 1 removed
  • Clinical Trials Research · Sacramento, United States
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    4 sites added, 1 site removed. 15 sites changed recruiting status (15 now recruiting)
    Show 15 sites
    • Banner Alzheimer's Institute · Phoenix, United StatesNot yet recruiting→Recruiting
    • Artemis Institute for Clinical Research · San Diego, United StatesNot yet recruiting→Recruiting
    • K2 Medical Research - Tampa · Tampa, United StatesNot yet recruiting→Recruiting
    • Covenant Medical Center · Waterloo, United StatesNot yet recruiting→Recruiting
    • MedVadis Research Corporation · Waltham, United StatesNot yet recruiting→Recruiting
    • Revival Research Institute, LLC · Southfield, United StatesNot yet recruiting→Recruiting
    • Monroe Biomedical Research · Monroe, United StatesNot yet recruiting→Recruiting
    • NDx Clinical Research, Inc. · Dayton, United StatesNot yet recruiting→Recruiting
    • Senior Adults Specialty Research · Austin, United StatesNot yet recruiting→Recruiting
    • Consano Clinical Research, LLC · Shavano Park, United StatesNot yet recruiting→Recruiting
    • Tokyo-Eki Center-building Clinic · Chūōku, JapanNot yet recruiting→Recruiting
    • P-One Clinic · Hachiōji, JapanNot yet recruiting→Recruiting
    • Yotsuya Internal Medicine Clinic · Shinjyuku, JapanNot yet recruiting→Recruiting
    • Tokyo Metropolitan Institute for Geriatrics and Gerontology · tabashi City, JapanNot yet recruiting→Recruiting
    • SCB Research Center · Bayamón, Puerto RicoNot yet recruiting→Recruiting
    Show 4 added (4 United States)
    • Headlands Research- Sacramento · Sacramento, United States
    • K2 Medical Research WINTER GARDEN · Clermont, United States
    • K2 Medical Research - Daytona Beach · Daytona Beach, United States
    • K2 MEDICAL Research THE VILLAGES · Lady Lake, United States
    Show 1 removed
    • Clinical Trials Research · Sacramento, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07602582
Responsible party
Sponsor
First posted
May 22, 2026
Start date
May 22, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion